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Abstract 
Purpose: AKT plays a pivotal role in the signal transduction of cancer cells. MK2206, an AKT inhibitor, has been 
shown to be an effective anti‑cancer drug to a variety of cancer cell lines. However, some cancer cells acquire resist‑
ance to MK2206 and new strategies to suppress these cell lines remain to be developed.
Experimental design: Acquired MK‑2206‑resistant neuroblastoma (NB) cell sublines were induced by stepwise 
escalation of MK‑2206 exposure (4–12 weeks). MTT assay was used to validate cell proliferation. Flow cytometry was 
performed for cell cycle analysis. Western blot assay was used for cell signaling study.
Results: MK2206 (5–10 µmol) significantly suppressed cell growth of MK2206 non‑resistant NB cells (LAN‑1, KP‑N‑
SIFA, NB‑19 and SK‑N‑DZ), but is less efficient in inhibiting that of resistant sublines, even after 2‑week MK2206‑free 
incubation. MK2206 acted in mTOR‑S6K dependent and independent methods. MK‑2206 resistant sublines (LAN‑
1‑MK, KP‑N‑SIFA‑MK, and SK‑N‑DZ‑MK) showed lower IC50 of GSK2334470 (PDK1 inhibitor). The cell growth of all sub‑
lines was prohibited by AZD8805 (mTOR inhibitor), with IC50 of AZD8805 3–10 times lower than MK2206 non‑resistant 
cells. The signaling profiles of these resistant sublines were characterized by elevated PDK1‑mTOR‑S6K activity, accom‑
panying by low phosphorylation of AKT compared with non‑resistant counterparts. GSK2334470 and AZD8055 effec‑
tively inhibited phosphorylation of PDK1 and mTOR, respectively, and induced higher G0–G1 ratio in LAN‑1‑MK than 
that in LAN‑1 as well. PDK1 and mTOR inhibitors effected on phosphorylation of GSK3β in some of resistant sublines.
Conclusion: NB cells can acquire MK2206 resistance after exposure for 4–12 weeks. Resistant cells feature reliance on 
PDK1‑mTOR‑S6K pathway and are more sensitive to PDK1 and mTOR inhibitors than the non‑resistant counterparts. 
Thus, suppression of PDK1‑mTOR‑S6K signaling pathway is an effective way to overcome the MK2206 resistance, and 
this may be a promising strategy for targeted therapy.
Keywords: Neuroblastoma, MK2206, Akt, PDK1, mTOR, Cell growth
© 2015 Qi et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The mechanisms underlying cancer are marked by com-
plex aberrations that activate critical cellular signaling 
pathways in tumorigenesis. The phosphatidylinositol 
3-kinase/protein kinase-B/mammalian target of rapa-
mycin (PI3K/AKT/mTOR) signaling cascade is one of 
the most important intracellular pathways, which is 
frequently activated in diverse cancers [1–3]. Activa-
tion of the PI3K/AKT/mTOR signaling pathway medi-
ated through molecular aberrations is instrumental in 
promoting tumor development as well as resistance to 
anticancer therapies [4]. The PI3K/AKT/mTOR path-
way can be activated by transmembrane tyrosine kinase 
growth factor receptors, such as ErbB family receptors, 
fibroblast growth factor receptors (FGFR), insulin-like 
growth factor 1 receptor (IGF-1R), and others [5, 6]. In 
addition, G protein-coupled receptors such as activated 
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RAS can stimulate PI3K through its catalytic subunit [7]. 
Mutations in PI3K/AKT/mTOR signaling can associate 
with disorders with a high incidence of cancers [8]. These 
mechanisms leading to aberrant PI3K/AKT/mTOR sign-
aling in affected cancer cells become the molecular tar-
gets of cancer therapy [9, 10].
Numerous efforts have been made to develop PI3K/
AKT/mTOR targeted therapies for cancer treatments. 
Various drugs such as PI3K, AKT, or mTOR kinase inhib-
itors are in clinical development, and have been approved 
by the Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA) for treating cancers, 
such as advanced renal cell cancer [11, 12], hormone 
receptor-positive [13], HER2-negative breast cancer, and 
neuroendocrine tumors of pancreatic origin [14]. AKT/
PKB (protein kinase-B) is a family composed of three ser-
ine/threonine kinases known as AKT1, AKT2 and AKT3. 
AKT is an important part of PI3K signaling as the activa-
tion of the protein is caused by PI3K and PDK1 mediated 
phosphorylation in the catalytic domain at threonine 308. 
AKT activation is involved in tumor progression through 
increased cell proliferation and survival, invasion, metab-
olism or angiogenesis [15]. AKT regulates downstream 
targets in the PI3K pathway such as TSC2 (which leads 
to activation of mTORC1) and outside of the PI3K path-
way such as Bcl-2-associated proteins, glycogen synthase 
kinase-3β (GSK3β) or mouse double minute 2 homolog 
(MDM2). Inhibition of AKT as an important node in 
PI3K signaling could have a significant impact on tumors 
that are addicted to PI3K/AKT/mTOR axis activity [1].
MK-2206 is an investigational allosteric inhibitor of 
AKT that requires the PH domain of AKT for activity, 
but does not interact with the ATP binding pocket. As 
a result, MK-2206 is highly selective for AKT inhibition, 
has higher potency against recombinant human AKT1 
and AKT2 isoforms than AKT3, has little off-target 
kinase activities, and is less vulnerable to feedback activa-
tion of AKT compared with ATP-competitive inhibitors 
[16]. As a single agent, and in combination with cytotoxic 
drug, MK-2206 is being tested to be effective both in vitro 
and in  vivo; both in adult tumors [17–22] and in spec-
trum of pediatric tumors [23, 24]. In clinical trial, stable 
disease was observed in different cancers [25, 26]. Phase I 
Studies showed doses of MK-2206 ranging between 0.25 
and 100 mg oral were well tolerated [27]. A larger phase 
I exploration is underway, examining MK-2206 dose for-
mulations and combinations with cytotoxic drug [24, 28].
PDK1  (3-phosphoinositide-dependent protein kinase 
1) activates a group of protein kinases belonging to the 
AGC [PKA (protein kinase A)/PKG (protein kinase G)/
PKC (protein kinase C)]-kinase family that play impor-
tant roles in mediating diverse biological processes [29, 
30]. Many cancer-driving mutations induce activation 
of  PDK1  targets including AKT [31], S6K (p70 ribo-
somal S6Kinase) [32] and SGK (serum- and glucocor-
ticoid-induced protein kinase) [33]. Small molecule 
GSK2334470 inhibits PDK1 with an IC50 of ~10 nM, but 
does not suppress the activity of 93 other protein kinases 
including 13 AGC-kinases most related to PDK1 at 500-
fold higher concentrations [34]. Addition of GSK2334470 
ablated T-loop residue phosphorylation and activation 
of SGK isoforms and S6K1 induced by serum or IGF-1 
(insulin-like growth factor 1) [35].
Mammalian target of rapamycin (mTOR) is also a ser-
ine/threonine protein kinase, modulating cancer cell pro-
liferation, mortality, survival and protein synthesis [36]. 
AZD8055 is a novel and potent ATP-competitive mTOR 
inhibitor, which blocks both mTORC1 and mTORC2 
activation [37], effecting on cancer cell growth and sur-
vival [38–40]. AZD8055 is a first-in-class orally available, 
potent and specific inhibitor of mTOR kinase activity, 
and shows a promise for suppressing tumor growth [41].
Establishment of resistant sublines is a common 
experimental method to investigate the mechanism of 
drug resistance. AKT inhibitor, such as MK-2206, shows 
promising effect on cancer therapy, but MK-2206 resist-
ance remains to be studied. In this study, we successfully 
induced MK-2206-resistant sublines by using stepwise 
exposure, and identified cell signaling features of resist-
ant sublines. The purpose of our study is to investigate 
the acquired mechanism of resistance to AKT inhibition 
and to explore strategies to overcome the tolerance of the 
AKT inhibitors in cancer therapy.
Methods
Cell lines and cell culture
The following four human NB cell lines were used and 
evaluated in this study. They are NB-19 [42], KP-N-SIFA 
[43], SK-N-DZ [44] and LAN-1 [45], which were stud-
ied in our previous papers [46, 47]. All these 4 cell lines 
were cultured in RPMI1640 (R8758, Sigma) medium sup-
plemented with 10 % fetal bovine serum (FBS) (GIBCO). 
Cells were incubated in a humidified atmosphere at 37 °C 
with 5 % CO2.
Induction of MK‑2206‑resistant NB cells
To induce acquired MK-2206-resistance, aliquots of par-
ent cells were seeded into 25 cm2 culture bottles, and 
cultured in 10 % FBS RPMI1640 medium with stepwise 
escalation of concentration of MK-2206 (from 1 to 5 μg). 
Fresh medium with MK-2206 was changed every 72  h. 
Cells were transferred into new culture bottles every 
7  days. We continued this process while observing cell 
death every day, and performing cell counting by using 
Invitrogen Cell Counter regularly. Escalation of MK-2206 
was performed after twice solid cell counting results 
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showing increasing cell number. Thus, after 4–12 weeks, 
MK-2206-resistant sublines were obtained that grew sta-
bly in MK-2206 (5 μg)-containing medium, and these 
resistant cells were named LAN-1-MK, NB-19-MK, KP-
N-SIFA-MK, and SK-N-DZ-MK.
Antibodies and reagents
The following antibodies and reagents were used in 
the present study: anti-AKT (#9272, Cell Signaling), 
anti-phospho-AKT (Ser473) (#4058, Cell Signaling), 
phospho-PDK1 (Ser241) (C49H2) (#3438, Cell Signal-
ing), phospho-mTOR (Ser2448) (#5536, Cell Signaling), 
phospho-p70 S6Kinase (Thr389) (#9205, Cell Signaling), 
anti-GSK-3β (27C10) (#9315, Cell Signaling), p-Ser9-
GSK-3-beta (#9322, Cell Signaling), anti-N-MYC(C-19) 
(SC-791, Santa Cruz Biotechnology), and anti- c-Myc 
(9E10) (sc-40, Santa Cruz Biotechnology).
MK-2206 (AKT inhibitor, A10003) was purchased from 
Selleckchem. GSK2334470 (PDK1 inhibitor, No. 4143) 
was purchased from Tocris Bioscience. AZD8055 (mTOR 
inhibitor, 1009298-09-2) was purchased from LC Labo-
ratories. U0126 (MEK inhibitor, 70970-5) was purchased 
from Cayman Chemical.
Cell counting
MTT cell counting reagent was obtained from Sigma-
Aldrich. Cells (5 × 103) were seeded in 100 μl medium in 
96 wells plates and pre-incubated for 6 h before the addi-
tion of inhibitors. MTT (20 μl, 5 mg/ml) was added into 
each well. After 3.5 h incubation in a humidified atmos-
phere at 37  °C with 5  % CO2, carefully removed media, 
and added DMSO (150 μl), then shaking for 15 min. The 
absorbance at 590  nm was measured using multi-spec-
trophotometer (Viento, Dainippon, Japan). The optical 
density was then used to extrapolate in the cell num-
ber from a standard curve. The standard curves were 
drawn for each cell line for each type of medium. The 
results are expressed as mean ± SD from 3 independent 
experiments.
Western blotting
Cytoplasmic extracts were obtained as previously 
reported [48]. The proteins (40  μg/lane) were run on 
7.5, 10 or 15  % sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis followed by semi-dry transfer to 
PVDF membrane (Invitrogen, Carlsbad, CA). Trans-
ferred PVDF blots were pretreated with 5 % non-fat dry 
milk in TBST containing 0.1 % Tween-20 and incubated 
with primary antibody (1:1000–3000) at 4  °C overnight. 
The membrane was then washed 3 times with TBST and 
incubated with horseradish peroxidase-conjugated sec-
ondary antibody (1:1000–3000) for 1 h at room tempera-
ture. For phosphorylated protein, transferred PVDF blots 
were pretreated with PVDF Blocking Reagent (TOYOBO, 
Osaka, Japan) for 1  h, and incubated with primary and 
then with secondary antibody (1: 3000–6000) which were 
diluted with Can Get Signal® Immunoreaction Enhancer 
Solution (TOYOBO, Osaka, Japan) at room tempera-
ture for 1 h. After washing three times again, antibodies 
bound to protein blots were detected by using Western 
Lightening Chemiluminescence Reagent Plus (Perkin 
Elmer Life Science, Boston, MA, USA), visualized on 
LAS-3000 mini (FUJIFILM). The blots were quantitated 
and cropped using Multi Gauge Ver 3.0 (FUJIFILM).
Cell cycle analysis
Cell cycle analysis was performed after treatment with/
without MK-2206 for 12  h. Cells (2  ×  106) were har-
vested and fixed in 99.5 % ethanol over night at −20 °C, 
followed by incubation with 500  μl propidium iodide 
(PI) Triton X-100 solution containing RNase A at room 
temperature for 30  min in darkness, then the DNA 
content was analyzed immediately with FACScan flow 
cytometer,analyzed by using ModFitLT software.
Statistical analyses
A two-sided paired t test was used to determine statisti-
cal significance. A P < 0.05 was considered as statistically 
significant.
Result
MK‑2206 sensitivity and acquired MK‑2206 resistance  
in NB cell lines
To study the inhibitory effect of MK-2206 on NB cell 
growth, cells (LAN-1, NB-19, KP-N-SIFA, and SK-N-
DZ) were selected and treated with MK-2206 at indicated 
concentrations for 72  h. MK-2206 treatment induced a 
dose dependent inhibition of cell proliferation, with IC50 
ranging from 1.22 μM (KP-N-SIFA) to 4.35 μM (NB-19) 
(Figs.  1a and 2b). These cells were deined as MK-2206 
non-resistant cells.   
To explore acquired MK-2206 resistance in NB cells, 
stepwise escalation of MK-2206 exposure (4–12  weeks) 
was applied to induce MK-2206 resistance. MK-2206-re-
sistant sublines (LAN-1-MK, NB-19-MK, KP-N-SIFA-
MK, and SK-N-DZ-MK) proliferated during 72  h 
incubation in RPMI1640 plus 10  % FBS medium in the 
presence of MK-2206 (5  μM), when non-resistant cell 
number declined, and difference were significant (Fig. 1c). 
MK-2206 suppressed cell growth in a dose dependent 
method, and significant difference was observed between 
MK-2206 non-resistant cells and resistant sublines in 
RPMI1640 plus 10  % FBS medium with MK-2206 at 
each indicated concentrations (Fig. 2a). MK-2206 IC50 of 
resistant sublines ranged from 8.35 μM (SK-N-DZ-MK) 
to 25.7  μM (KP-N-SIFA-MK) (Fig.  2b). Furthermore, 



























































































































0 μM 1.25 μM 2.5 μM 5 μM 7.5 μM 10 μM 15 μM 20 μM 30 μM 40 μM 















Fig. 1 MK‑2206 suppressed the cell growth of NB cells. a MK‑2206 suppressed the cell growth of NB cell lines. LAN‑1, KP‑N‑SIFA, NB‑19, and SK‑N‑
DZ cells were cultured in RPMI1640 + 10 % FBS with MK‑2206 at indicated concentrations. Cell growth was evaluated as cell numbers at 72 h, and it 
was repeated three times. Data are expressed as the mean (±SD). b Photomicrographs of MK‑2206 non‑resistant and resistant cells. Cells were cul‑
tured in glass bottom slide chambers with RPMI1640 + 10 % FBS, with MK‑2206 (resistant sublines)/without MK‑2206 (non‑resistant cells) overnight. 
A 50 µm scale is indicated (Olympus Fluoview fv1000, DIC acquisition, ×40)
Page 5 of 14Qi et al. Cancer Cell Int  (2015) 15:91 
MK2206 IC50 (µM) 
LAN-1       LAN-1-MK KP-N-SIFA       KP-N-SIFA-MK NB-19      NB-19-MK SK-N-DZ    SK-N-DZ-MK 
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Fig. 2 MK‑2206 showed less inhibition in cell growth of MK‑2206‑resistant sublines. a MK‑2206 showed less inhibition in the proliferation of MK‑
2206‑resistant sublines than in the non‑resistant cells. Indicated cells were cultured in RPMI1640 + 10 % FBS with MK‑2206 at indicated concen‑
trations. Cell growth was evaluated as cell numbers at indicated hours, and it was repeated three times. Data are expressed as the mean (±SD). 
*P < 0.01. b MK2206 suppressed cell growth in a dose dependent method, and MK‑2206‑resistant sublines maintained resistance after 2‑week with‑
drawal of MK‑2206. Indicated cells were cultured in RPMI1640 + 10 % FBS with MK‑2206 at the indicated concentrations. Cell growth was evaluated 
as cell numbers at 72 h, and it was repeated three times. Data are expressed as the mean (±SD)
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2  weeks of MK-2206-free culture could not completely 
restore the sensitivity of MK-2206 in the resistant sub-
lines, named as LAN-1-MK-Free, NB-19-MK-Free, KP-N-
SIFA-MK-Free, and SK-N-DZ-MK-Free (Fig. 2a).
Additionally, we compared morphologies of MK-2206 
non-resistant and resistant cells. LAN-1 and SK-N-DZ 
were reported to be N type cells [49, 50]. In our study, 
MK-2206 non-resistant cells and resistant sublines 
showed a very similar phenotype in culture, character-
ized by variable shape, short neurite processes forma-
tion, and with no apparent directional orientation. Only 
exception is SK-N-DZ-MK, which showed smaller and 
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Fig. 3 Effect of GSK2334470 (GSK) on PDK1‑mTOR‑S6K axis in MK‑2206‑resistant sublines. a–d After 1 h serum starvation, indicated cells were 
incubated in RPMI1640 + 10 % FBS with/without MK‑2206 (5 μM) or GSK (5 μM). Phosphorylation of PDK1, AKT, mTOR, and S6K were detected by 
western blot at 1.5 and 12 h, so were AKT and Actin. GSK3β, p‑GSK3β and N‑MYC were also detected
Page 7 of 14Qi et al. Cancer Cell Int  (2015) 15:91 
MK-2206 was reported to affect cell-cycle distribution 
[51]. In our study, cell-cycle analysis showed that MK-2206 
(5 μM) caused G0–G1 accumulation from 33.93 to 63.64 % 
in LAN-1 cells, but not in LAN-1-MK subline (Fig. 2c, d).
PDK1 inhibitor (GSK2334470) prohibited cell growth 
of MK‑2206‑resistant sublines
PDK1, regulated by PI3K, phosphorylates and activates 
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Fig. 4 Effect of GSK2334470 (GSK), PDK1 inhibitor, in MK‑2206‑resistant sublines compared with non‑resistant cells. a Indicated cells were treated 
with GSK at indicated concentrations, with/without MK‑2206 (5 μM) in RPMI1640 + 10 % FBS. Cell growth was evaluated as cell numbers at 72 h, 
and it was repeated three times. Data are expressed as the mean (±SD). b The effect of GSK on cell cycle phase distribution in LAN‑1 and LAN‑MK. 
LAN‑1 and LAN‑1‑MK were treated with GSK (5 μM) with/without MK‑2206 (5 μM) in RPMI1640 with 10 % FBS for 12 h followed by analysis of cell 
cycle phase distribution, as introduced in methods and material. Indicated cells were stained with PI for 30 min followed by FACScan flow cytom‑
eter. c IC50 of GSK in indicated cells
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a bLAN-1 KP-N-SIFA
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Fig. 5 Effect of AZD8055 (AZD), mTOR inhibitor, in MK‑2206‑resistant sublines compared with non‑resistant cells. a Indicated cell lines were treated 
with AZD at indicated concentrations, with/without MK‑2206 (5 μM) in RPMI1640 + 10 % FBS. Cell growth was evaluated as cell numbers at 72 h, 
and it was repeated three times. Data are expressed as the mean (±SD). b The effect of AZD on cell cycle phase distribution in LAN‑1 and LAN‑MK. 
Indicated cells were treated with AZD (50 nM) with/without MK‑2206 (5 μM) in RPMI1640 with 10 % FBS for 12 h followed by analysis of cell cycle 
phase distribution, as introduced in methods and material. Cells were stained with PI for 30 min followed by FACScan flow cytometer. c IC50 of AZD 
of indicated cell lines
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a                                         bLAN-1                            KP-N-SIFA
1.5 hr 12 hr                          1.5 hr 12 hr
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Fig. 6 Effect of AZD8055 (AZD) on mTOR‑S6K axis in MK‑2206‑resistant sublines. a–d After 1 h serum starvation, indicated cell lines were incubated 
in RPMI1640 + 10 % FBS with/without MK‑2206 (5 μM) or AZD (50 nM). Phosphorylation of mTOR and S6K were detected by western blot at 1.5 and 
12 h, so was Actin. e Effect of U0126 on NB‑19‑MK cell line compared with NB‑19. Indicated cells were treated with U0126 at indicated concentra‑
tions in RPMI1640 + 10 % FBS, with/without MK‑2206 (5 μM). Cell growth was evaluated as cell number at 72 h, and result was repeated three 
times. Data are expressed as the mean (±SD). f NB‑19 and NB‑19‑MK were incubated in RPMI1640 + 10 % FBS with/without MK‑2206 (5 μM) or 
U0126 (5 μM). Phosphorylation of ERK, AKT, and S6K were detected by western blot at 1.5 and 12 h, so was Actin
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including AKT and mTOR [30]. In this study, to assess 
PDK1 activity in MK-2206 resistance, non-resistant 
cells and resistant sublines were treated with/without 
GSK2334470 (PDK1 inhibitor) for 72  h, and cell viabil-
ity was detected by MTT assay. GSK2334470 attenuated 
cell growth of non-resistant cells (LAN-1, KP-N-SIFA, 
NB-19, and SK-N-DZ), and more of resistant sublines 
(LAN-1-MK, KP-N-SIFA-MK, and SK-N-DZ-MK), 
combined with MK-2206 (5  μM), in a dose dependent 
method, which were significantly different at each indi-
cated concentration (Fig.  3a). IC50 of GSK2334470 in 
MK-2206-resistant sublines ranged from 1.64 (SK-N-DZ-
MK) to 5.1 μM (KP-N-SIFA-MK), which was lower than 
that of MK-2206 non-resistant cells with the IC50 ranging 
from 2.90 (SK-N-DZ) to 17.4 μM (KP-N-SIFA) (Fig. 3b). 
GSK2334470 induced G0–G1 accumulation of cell 
cycle phase distribution in LAN-1 increasing from 39.33 
to 54.52  % (Figs.  2c, 3c). In LAN-1-MK, GSK2334470 
induced G0–G1 accumulation increasing from 36.10 to 
44.75  % without MK-2206, and from 40.91 to 48.51  % 
with MK-2206 (Figs. 2b, 3c).
The mTOR inhibitor (AZD8055) prohibited cell growth 
of MK‑2206‑resistant sublines
Signaling pathway of PI3K/AKT/mTOR is frequently 
dysregulated in different disorders of cell growth, sur-
vival, and resistance. To study the role of mTOR in the 
MK-2206 resistance, MK-2206 non-resistant cells and 
resistant sublines were treated with AZD8055 (mTOR 
inhibitor) for 72  h, and cell viability was detected by 
MTT assay. AZD8055 suppressed cell growth of non-
resistant cells (LAN-1, KP-N-SIFA, NB-19, and SK-
N-DZ), and more of resistant sublines (LAN-1-MK, 
KP-N-SIFA-MK, NB-19-MK and SK-N-DZ-MK) in 
a dose dependent method, combined with MK-2206 
(5 μM), which were significantly different at each indi-
cated concentration (Fig. 4a). AZD8055 prohibited cell 
growth of LAN-1, NB-19, KP-N-SIFA, and SK-N-DZ 
with IC50 ranging from 33.78 (SK-N-DZ) to 154.23 nM 
(NB-19), while IC50 of AZD8055 of MK-2206 resist-
ant sublines ranged from 4.91  nM (SK-N-DZ-MK) to 
49.32 nM (KP-N-SIFA-MK) (Fig. 4b).  
AZD8055 induced G0–G1 accumulation in LAN-
1cell cycle phase distribution from 39.33 to 51.54  % 
(Figs.  2c, 4c). AZD8055 also induced an increase in 
G0–G1 phase from 36.10 to 47.95 % without MK-2206 
and from 40.91 to 58.57  % with MK-2206 in LAN-
1-MK (Figs. 2c, 4c).
Decrease in AKT phosphorylation in MK‑2206‑resistant 
sublines
To study inhibitory effect of MK-2206 on AKT path-
way, cells were culture in RPMI + 10 % FBS with/with-
out MK-2206, after 1  h serum starvation. P-AKT was 
detected by an anti-p-AKT antibody. AKT phosphoryla-
tion was suppressed by 5 μM of MK-2206 in LAN-1, KP-
N-SIFA, NB-19, and SK-N-DZ cells (Fig. 5a–d). Stepwise 
escalation of MK-2206 exposure reduced p-AKT and 
total AKT levels in LAN-1-MK, NB-19-MK and SK-N-
DZ-MK, comparing with the non-resistant opponents, 
after 1.5 and 12 h incubation without MK-2206 (Fig. 5a, 
c, d). KP-N-SIFA-MK had low levels of p-AKT but high 
levels of total AKT than its non-resistant counterpart 
(Fig. 5b).
Fig. 7 Schematic pathway alternations of MK‑2206 resistance. a 
Signal pathway study of MK‑2206 non‑resistant cells showed that 
AKT acted in mTOR‑S6K dependent method (LAN‑1 and SK‑N‑DZ), 
in which inhibition of AKT reduced activity of mTOR‑S6K signaling. 
Activity of PDK1 took the place of AKT, and elevated PDK1‑mTOR‑S6K 
transduction contributed to MK‑2206 resistance, when AKT‑mTOR‑
S6K was blocked. b AKT acted in mTOR‑S6K independent method 
(KP‑N‑SIFA and NB‑19), in which inhibition of AKT did not impair 
the activity of mTOR‑S6K signaling. Parallel signaling pathway of 
PDK1‑MTOR‑S6K became an important alternative for cell growth of 
MK‑2206‑resistant sublines, when AKT was inhibited. And some other 
signal pathway may contribute to MK‑2206 resistance as well
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AKT acted in mTOR‑S6K dependent and independent 
manners in NB cells 
In LAN-1 and SK-N-DZ, phosphorylation of mTOR and 
S6K (p-mTOR and p-S6K) were reduced by MK-2206 
at 5 μM; in LAN-1-MK and SK-N-DZ-MK, p-mTOR 
and p-S6K were higher than those in their non-resistant 
counterparts, and not suppressed by MK-2206 at 5 μM 
(Fig.  5a, d). In the meantime, p-mTOR and p-S6K were 
not affected by MK-2206 (5 μM) in NB-19, KP-N-SIFA 
and their resistant sublines (Fig. 5b, c). It suggested that 
AKT acted in mTOR-S6K dependent method (LAN-1 
and SK-N-DZ), in which inhibition of AKT reduced 
activity of mTOR-S6K signaling; mTOR-S6K independent 
method (KP-N-SIFA and NB-19), in which inhibition of 
AKT did not impair the phosphorylation of mTOR-S6K 
signaling.
PDK1 inhibitor (GSK2334470) suppressed mTOR‑S6K 
pathway in MK‑2206‑resistant sublines
To study the inhibitory effect of GSK2334470 on mTOR-
S6K pathway, non-resistant cells (LAN-1, NB-19, KP-
N-SIFA, and SK-N-DZ) and the resistant sublines 
(LAN-1-MK, NB-19-MK, KP-N-SIFA-MK, and SK-N-
DZ-MK) were treated with GSK2334470 at 5 μM for 1.5 
and 12  h in 10  % FBS medium with/without MK-2206 
(5 μM). Decrease of phosphorylated PDK1, mTOR, and 
S6K (p-PDK1, p-mTOR, and p-S6K) was detected in both 
MK-2206 non-resistant cells and resistant sublines after 
12 hours treatment of GSK2334470 (5 μM) (Fig.  5a–d). 
MK-2206-resistant sublines had relative high levels of 
p-PDK1 than the non-resistant sublines (Fig.  5a–d). 
GSK2334470 suppressed p-mTOR and p-S6K in both 
MK-2206 non-resistant cells (LAN-1, KP-N-SIFA, NB-19 
and SK-N-DZ) and their resistant sublines (Fig. 5a–d). It 
indicated that PDK1 played an important role in mTOR-
S6K signaling with or without AKT activity.
MTOR inhibitor (AZD8055) suppressed mTOR‑S6K pathway 
in MK‑2206‑resistant sublines
To study the inhibition effect of AZD8055 on mTOR-
S6K pathway, MK-2206 non-resistant cells and resist-
ant sublines were cultured with/without AZD8055 at 
50 nM in 10 % FBS medium with/without MK-2206 for 
1.5 and 12 h, and phosphorylation of mTOR-S6K signal-
ing was tested by western blot. A decrease in p-mTOR 
was detected in MK-2206 non-resistant cells and resist-
ant sublines with AZD8055. P-S6K was also inhibited 
by AZD8055 in these cell lines, including NB-19-MK 
(Fig. 6a–d).
GSK‑3β and N‑MYC expressions in MK‑2206‑resistant cells
GSK3β (glycogen synthase kinase 3β) is expressed 
ubiquitously and highly conserved, whose activities is 
regulated by diverse stimuli and signaling pathways. 
GSK3β (S9) is mainly phosphorylated and inactivated 
by PI3K-AKT signal pathway; Raf/MEK and other path-
ways may also induce the phosphorylation and inactivity 
of GSK3β [52]. To see if GSK3β is a potential component 
in MK-2206 resistance, we tested GSK3β and pS9-GSK3β 
in both MK-2206 non-resistant cells and resistant sub-
lines. The result showed that phosphorylation of GSK3β 
has less relationship with AKT activity in KP-N-SIFA and 
SK-N-DZ, because MK-2206 barely reduced pS9-GSK3β 
(Fig.  4b, d). In LAN-1-MK and NB-19-MK, pS9-GSK3β 
level did not show any change with/without MK-2206, 
but their MK-2206 non-resistant opponents did show 
decline with MK-2206 co-incubation (Fig. 5a, c). Never-
theless, pS9-GSK3β of LAN-1-MK and NB-19-MK was 
suppressed by PDK1 and mTOR inhibitors (Figs.  5a, c, 
6a, c), indicating compensation of PDK1 or mTOR in 
absence of AKT phosphorylase activity.
Transcription factors of N-MYC and C-MYC were 
previously shown to contribute to tumourigenesis and 
progression in NB [53, 54]. LAN-1, NB-19, and SK-N-
DZ were reported high N-MYC expression [50]. MYC 
activity is usually regulated by GSK3β. In our study, 
expressions of N-MYC and C-MYC did not show solid 
relationship between pS9-GSK3β and MK-2206 resist-
ance (Figs. 5, 6).
MAPK inhibitor (U0126) prohibited cell growth 
in NB‑19‑MK cells
As cell growth of NB-19-MK was not sensitive to 
GSK2334470, it is possible that other signal pathway 
might be involved in MK-2206 resistance. MAPK inhibi-
tor (U0126) effectively suppressed cell growth of NB-
19-MK, which U0126 at 5  μM significantly suppressed 
cell growth of NB-19-MK compared with NB-19 (Fig. 6e), 
but it did not affect p-S6K (Fig.  6f ), indicating MAPK 
related resistance.
Discussion
In this study, MK-2206 showed inhibitory effect on cell 
growth of NB cell lines. Signal pathway study of MK-2206 
non-resistant cells showed that AKT acted in mTOR-
S6K dependent method (LAN-1 and SK-N-DZ), in which 
inhibition of AKT reduced activity of mTOR-S6K signal-
ing; and mTOR-S6K independent method (KP-N-SIFA 
and NB-19), in which inhibition of AKT did not impair 
the activity of mTOR-S6K signaling. Step-wise exposure 
to MK-2206 induced acquired resistance in non-resistant 
cells. MK-2206-resistant sublines showed much lower 
IC50 of PDK1 and mTOR inhibitors, especially mTOR 
inhibitor (AZD8055). Signal pathway study of resist-
ant sublines showed that LAN-1-MK and SK-N-DZ-
MK expressed elevated PDK1-mTOR-S6K transduction 
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(Fig. 7a), which indicated that activity of PDK1 took the 
place of AKT, and PDK1-mTOR-S6K signaling made con-
tribution to cell growth of their resistant sublines. KP-
N-SIFA-MK did not show amplification of mTOR-S6K 
signaling, but its elevated sensitivity to PDK1 and mTOR 
inhibitors implied that PDK1-mTOR-S6K transduction 
became an important alternative for cell growth of KP-
N-SIFA-MK. Cell growth of NB-19-MK was related to 
MAPK pathway (Fig.  7b). Thus, continuous administra-
tion inducing signaling pathway alternation may offset 
MK-2206 inhibitory effect on cell growth, and MK-2206 
resistance was not be overcome by short period interrup-
tion of administration (2 weeks). These observations sug-
gest that NB cells may be able to enact mechanism base 
on signal transduction alternation to NB cell survive and 
escape cell death from singly MK-2206 exposure.
AKT acts as an important role in cell signal transduc-
tion, accelerating cancer cell growth. MK-2206 is an 
allosteric inhibitor of AKT, proved to be an effective rea-
gent to suppress cancer cell growth [22, 25, 26], with syn-
ergy observed in combination other targeted therapies 
in preclinical models [18, 26]. According to our obser-
vation, singly exposure MK-2206 may induce acquired 
resistance of NB cells in 4–12 weeks. Combination with 
PDK1 or mTOR inhibitor is feasible method to com-
pensate MK-2206 resistance in NB cells. Since in most 
tumors multiple signaling pathways are involved, many 
of the inhibitors in clinical development are designed to 
affect a wide range of targeted kinases [55]. Multi-tar-
geted tyrosine kinase inhibitors are promising to resolve 
similar resistance. It was reported that the strategy of 
dual PI3K and mTOR inhibition targets the pathway at 
two different levels with the potential to effectively over-
come the feedback inhibition ordinary observed when 
mTORC1 inhibitors are used alone, which limits their 
efficacy [56].
PDK1 is considered as the master upstream regulator 
of AGC kinase signal transduction, which phosphoryl-
ates and activates a diverse set of AGC kinase members 
regulated by PI3-kinase, when the interaction of insulin 
and growth factors with their receptors on the outside 
surface of a cell [30]. PDK1 is constitutively active, thus, 
AKT and S6K can be activated downstream of PI3K by 
PDK1. GSK2334470 not only inhibits T-loop phospho-
rylation and activation of AKT but also those of the 
RSK2 (p90 ribosomal S6Kinase2) [35]. Our observation 
showed that PDK1 inhibitor (GSK2334470) is effective 
in suppressing cell growth of both MK-2206-resistant 
and non-resistant cells. Suppression of PDK1 affected 
mTOR-S6K signaling in all MK-2206 non-resistant cells 
and resistant sublines. In the meantime, GSK2334470 
not only prohibited cell growth but induced G0–G1 
cell cycle accumulation as the effect of MK-2206 in 
non-resistant cells. These indicated that PDK1 could be 
important target in NB therapy.
In our observation, alternation of signaling path-
ways is the main reason of MK-2206 resistance, 
including PDK1-mTOR-S6K pathway activation 
(LAN-1-MK, SK-N-DZ-MK, and KP-N-SIFA-MK), 
MAPK pathway activation (NB-19-MK). Interestingly, 
mTOR-S6K works as the mutual signal transduc-
tion in MK-2206-resistant sublines, because mTOR 
inhibitor, AZD8055, is effective to cell growth of these 
MK-2206-resistant sublines. Dysregulation of mTOR 
signaling occurs in various tumor types, includ-
ing breast cancer, and has been associated with can-
cer pathogenesis, disease progression, and treatment 
resistance [57]. Signaling transduction of mTOR-S6K 
plays an important role in MK-2206 resistance, and 
its inhibitor, AZD8055, may be promising in molecu-
lar targeted therapy. Nevertheless, there is possibility 
that other mechanisms may contribute to MK-2206 
resistance as well. In this study, GSK3β and MYC were 
tested to find the relationship with MK-2206 resist-
ance, but no solid evidence was found. Meanwhile, 
we observed that MK-2206 did not effect in cell pro-
liferation at 5  μM in high confluence non-resistant 
cells, which indicated cell to cell interaction may be 
anther direction, and will be introduced in our next 
publications.
In summary, we showed AKT played an important role 
in cell growth of NB cells. MK-2206 is effective in sup-
pression of NB cell growth, but simply administration 
of MK-2206 might cause resistance to AKT targeted 
treatment. Cell growth of MK-2206-resistant sublines 
was related to reliance on PDK1-mTOR-S6K pathway. 
Both upstream (PDK1) and downstream (mTOR) AGC 
kinase inhibitors are inhibitive to the cell growth of MK-
2206-resistant sublines. We speculate that combination 
of PDK1-AKT-mTOR-S6K signaling inhibitors or multi-
targeted tyrosine kinase inhibitors is promising to resolve 
MK-2206 resistance.
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